Tat-Beclin 1 D11 (Tat-D11) and Tat-Beclin 1 L11 (Tat-L11) peptides specifically induce autophagy and can be used both in vitro and in vivo. Tat-D11 and Tat-L11 peptides are composed of the autophagy-inducing region of Beclin 1 fused to the HIV-Tat protein to facilitate cell permeability. Both peptides demonstrate improved specificity relative to other methods of autophagy induction, as well as enhanced potency over other Beclin 1-derived autophagy inducing peptides.
Cell permeable Tat-D11 peptides compete with the autophagy inducer, Beclin 1 for binding to the negative regulator of autophagy, GAPR-1/GLIPR2. Tat-D11 peptides free Beclin-1 from GAPR-1, resulting in Beclin-1 mediated autophagy induction.
Tat-Beclin 1 D11 (Tat-D11): Peptides comprising 11 amino acids derived from the autophagy inducer Beclin 1 linked to the HIV Tat protein to increase solubility. Tat-D11 is in the D-amino acid retro-inverso configuration.
Tat-Beclin 1 L11 (Tat-L11): Peptides comprising 11 amino acids derived from the autophagy inducer Beclin 1 linked to the HIV Tat protein to increase solubility. Tat-L11 is in the naturally occurring L-configuration.
Tat-Beclin 1 L11S (Tat-L11S): An inactive, scrambled control peptide derived from Tat-L11. Tat-L11S is recommended as a negative control for Tat-D11 and Tat-L11.
Figure 1. GAPR-1/GLIPR2 is a negative regulator of autophagy and binds Beclin 1 to inhibit autophagy. In the presence of Tat-D11 peptides, Beclin 1 bound to GAPR-1 is released allowing Beclin 1 to mediate autophagosome formation and autophagy induction.
BENEFITS OF TAT-D11 & TAT-L11
Potency: Superior potency of Tat-D11 peptides to induce autophagy relative to other Tat-Beclin 1 peptides.
Dose: Less Tat-D11 peptide required for equal autophagy induction relative to other Tat-Beclin 1 peptides.
Specificity: Specific autophagy induction with less off-target regulation of other biological processes relative to other autophagy induction methods (e.g. rapamycin, starvation, etc)
Figure 2. Tat-D11 and Tat-L11 are specific and potent autophagy inducers. HeLa GFP-LC3B were treated with Tat-D11, Tat-L11, Tat-L11S, or Tat-Beclin 1 for 1.5 hr, and the number of GFP+/ LC3B+ spots were quantified by fluorescent microscopy.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.